FDA allows marketing of device to help assess children and teens for ADHD

Author(s):

On June 15, the U.S. Food and Drug Administration (FDA) allowed marketing of the first medical device based on brain function to help assess attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old. The Neuropsychiatric EEG-Based Assessment Aid (NEBA) System is a 15- to 20-minute noninvasive test that calculates the ratio of theta and beta waves. The theta/beta ratio has been shown to be higher in children and adolescents with ADHD. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here